Esker Therapeutics Announces Name Change To Alumis And Completion Of $200 Million Series B Financing To Advance Precision Medicines For Autoimmune Diseases

Alumis, formerly Esker Therapeutics, a precision immunology company backed by Foresite Capital and incubated by Foresite Labs that is reimagining the discovery, development and treatment of autoimmune disorders, today announced the completion of a $200 million financing led by AyurMaya, an affiliate of Matrix Capital Management, and by a U.S.-based healthcare-focused fund. In conjunction with the financing, Alumis announced that Dr. Alan Colowick, managing director at Matrix, joined the company’s board of directors.